Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
286
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Richter transformation to Hodgkin lymphoma on Bruton’s tyrosine kinase inhibitor therapy

Alankrita Tanejaa Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; ORCID Iconhttps://orcid.org/0000-0002-7231-2623
ORCID Icon,
Jade Jonesb Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA;
,
Stefania Pittalugac Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;
,
Irina Maricd Department of Laboratory Medicine, Clinical Center National Institutes of Health, Bethesda, MD, USA
,
Mohammed Farooquia Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA;
,
Inhye E. Ahna Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA;
,
Adrian Wiestnera Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA;
&
Clare Suna Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Correspondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8498-4729
ORCID Icon show all
Pages 519-522 | Received 19 Apr 2018, Accepted 15 May 2018, Published online: 06 Jul 2018

References

  • Sachanas S, Pangalis GA, Moschogiannis M, et al. Hodgkin lymphoma transformation of chronic lymphocytic leukemia under ibrutinib therapy: chance association or therapy-related? AR. 2017;37:3277–3280.
  • Glavey S, Quinn J, McCloy M, et al. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. Eur J Haematol. 2017;99:378–380.
  • Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129:1469–1479.
  • Anderson MA, Tam C, Lew TE, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017;129:3362–3370.
  • Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874–879.
  • Smith CIE. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). Semin Cancer Biol. 2017;45:36–49.
  • Innocenti I, Rossi D, Trape G, et al. Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematol Oncol. 2018. [Feb 27]. doi: 10.1002/hon.2502
  • Momose H, Jaffe ES, Shin SS, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed–Sternberg-like cells and possible transformation to Hodgkin's disease. Mediation by Epstein–Barr virus. Am J Surg Pathol. 1992;16:859–867.
  • Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol. 2012;156:50–66.
  • Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. JCO. 2017;35:826–833.
  • Tsang M, Shanafelt TD, Call TG, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125:1676–1678.
  • Giri S, Hahn A, Yaghmour G, et al. Ibrutinib has some activity in Richter's syndrome. Blood Cancer J. 2015;5:e277.
  • Hamadani M, Balasubramanian S, Hari PN. Ibrutinib in refractory classic Hodgkin's lymphoma. N Engl J Med. 2015;373:1381–1382.
  • Master S, Leary C, Takalkar A, et al. Successful treatment of Richter transformation with ibrutinib in a patient with chronic lymphocytic leukemia following allogeneic hematopoietic stem cell transplant. Case Rep Oncol. 2017;10:534–541.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.